Characteristics and Outcomes of Recipients of Heart Transplant with Coronarvirus Disease 2019 Who Received Casirivimab Plus Imdevimab Infusion

PURPOSE: Heart transplant (HT) recipient are at increased risk of adverse outcomes following COVID-19 infection and may benefit from monoclonal antibody infusion to mitigate progression to clinically severe disease. The aim of this study is to describe the outcomes of HT patients who experienced mil...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaine, M., Bae, D., Oh, D., Lotan, D., Atanda, A., Oren, D., Latif, F., Yuzefpolskaya, M., Habal, M., Griffin, J., Majure, D., Colombo, P., Jennings, D., Choe, J., Clerkin, K., Fried, J., Raikhelkar, J., Lee, S., Restaino, S., Sayer, G., Uriel, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
(822)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988630/
http://dx.doi.org/10.1016/j.healun.2022.01.1401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988630/
http://dx.doi.org/10.1016/j.healun.2022.01.1401

Ejemplares similares